feedback

Course Director

James O. Armitage, MD
James O. Armitage, MD

University of Nebraska Medical Center
Omaha, Nebraska

Faculty

John G. Gribben
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci

Barts Health NHS Trust
Barts and The London School of Medicine, Queen Mary University of London
London, England, United Kingdom

Brad Kahl
Brad Kahl, MD

Washington University School of Medicine
St. Louis, Missouri

Jennifer Woyach
Jennifer Woyach, Jennifer Woyach, MD

The Ohio State University
Columbus, Ohio

Accredited by

University of Nebraska Medical Center

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2016-Aug-29
Expiration Date:2017-Aug-28
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Recent scientific developments have substantially altered the clinical landscape in chronic lymphocytic leukemia (CLL), a disease that often afflicts elderly individuals and may present with high-risk features. The emergence of highly active, novel agent classes and next-generation therapeutics has allowed clinicians greater flexibility when selecting therapy for patients with newly diagnosed or relapsed/refractory disease, including in settings where traditional immunochemotherapy may prove ineffective or overly toxic. This activity is based on a symposium at the recent Pan Pacific Lymphoma Conference 2016, and features expert insight on how to make informed treatment choices with a wider range of options in CLL, including next-generation antibodies, B-cell receptor (BCR) inhibitors, targeted therapies, and other innovative agents in the context of daily patient care.

Upon completion of this activity, participants should be better able to:
  • Cite new safety and efficacy evidence on the use of novel therapies in CLL, including next-generation antibodies, BCR inhibitors, targeted therapies, and other emerging therapeutics
  • Identify factors that may influence the selection or composition of therapy in CLL, including older age, cytogenetic/molecular features, or the presence of comorbid conditions
  • Select individualized therapeutic regimens with novel components for patients with CLL who present with newly diagnosed or relapsed/refractory disease
  • Recommend clinical trial–based therapeutic options for eligible patients with CLL

Target Audience

This activity has been designed to meet the educational needs of oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: August 29, 2016 - August 28, 2017
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other individuals who are in a position to control the content of this activity are required to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and resolved according to UNMC CCE policy. The existence or absence of COI for anyone in a position to control content will be disclosed to participants prior to the start of the activity.

Course Director and Moderator
James O. Armitage, MD
The Joe Shapiro Professor of Medicine
Division of Oncology/Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

James O. Armitage, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Conatus Pharmaceuticals Inc. (IDMC) and ZIOPHARM Oncology, Inc.
Other Financial or Material Support from Board of Directors for TESARO, Inc.

Faculty
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Hamilton Fairley Professor of Medical Oncology
Barts Health NHS Trust
Barts and The London School of Medicine, Queen Mary University of London
London, England, United Kingdom

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci, has a financial interest/relationship or affiliation in the form of:
Consultant for Celgene Corporation; TG Therapeutics, Inc.; and Unum Therapeutics Inc.
Grant/Research Support from Janssen Pharmaceuticals, Inc. and Pharmacyclics ​LLC.
Advisory Board for AbbVie; F. Hoffmann-La Roche Ltd/Genentech; Gilead Sciences, Inc; Janssen Pharmaceuticals, Inc.; Pharmacyclics ​LLC; and TG Therapeutics, Inc.
Other Financial or Material Support from AbbVie; Celgene Corporation; Epizyme,Inc.; F. Hoffmann-La Roche Ltd/Genentech; Gilead Sciences, Inc; Pharmacyclics ​LLC; and Takeda Pharmaceutical Company Limited for clinical trial support.

Brad Kahl, MD
Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri

Brad Kahl, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for F. Hoffmann-La Roche Ltd/Genentech, Inc.; Infinity Pharmaceuticals, Inc.; Pharmacyclics​ LLC ; and Teva Pharmaceuticals USA.
Grant/Research Support from AbbVie Inc. and Pharmacyclics​ LLC.

Jennifer Woyach, MD
Associate Professor of Medicine
Department of Internal Medicine
Division of Hematology
The Ohio State University
Columbus, Ohio

Jennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Acerta Pharma; Karyopharm Therapeutics; and MorphoSys AG.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Staff of the UNMC Center for Continuing Education have nothing to disclose.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PVI, PeerView Institute for Medical Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership
This CME activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and PVI, PeerView Institute for Medical Education.

Support
This activity is supported by educational grants from AbbVie Inc., Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2016, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.